Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 2 Trials for Cabazitaxel (DB06772)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting2 IdentifierTitlePurposeDrugs
NCT02703623Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate CancerTreatment
NCT03050866Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)Diagnostic